Keyword: Takeda

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

The deal grants Takeda rights to up to four programs, including natural killer cell therapies aimed at CD19 and BCMA.

As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Micro cap anti-infective biotech Aridis Pharmaceuticals has gained a new chief medical officer in the form of former Takeda Vaccines exec Paul Mendelm

The agreement tasks Prometheus with identifying and validating three IBD drug targets in return for up to $420 million in milestones.

Third Rock startup Goldfinch plans to file an IND for its treatment for rare and metabolic kidney diseases in the second half of next year.

As Celgene gradually phases into parent company Bristol-Myers Squibb, this is leaving little room at the inn for some of the top execs.

After helping develop one of the most widely used HIV drugs in the world Brian Johns, Ph.D., is stepping into the biotech world.

Takeda’s cytomegalovirus drug beat Roche’s Valcyte at clearing the virus in patients who had undergone an organ transplant or stem cell transplant.